Physician profile
Brian J Granger
NPI 1366775280
$17,353.21
in general payments reported to CMS, 2019-2025
47 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,565 · 2020: $2,941 · 2021: $4,130 · 2022: $1,683 · 2023: $2,202 · 2024: $1,480 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,984 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,984.47 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,929.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $1,618.73 | 2019-2023 | |
| Novo Nordisk INC | $1,618.16 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $1,607.31 | 2019-2025 | Farxiga, Fasenra, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,338.23 | 2021 | |
| Glaxosmithkline, LLC. | $1,204.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $887.21 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $865.41 | 2019-2025 | |
| Abbott Laboratories | $724.09 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $623.11 | 2019-2023 | Xifaxan, Relistor |
| Abbvie INC. | $595.09 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $498.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.25 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $368.37 | 2019-2023 | Verquvo, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $368.12 | 2019-2025 | Trintellix |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Granger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.